Prior systemic therapy
| . | Group 1: ibrutinib → ofatumumab (N = 27) . | Group 2: ibrutinib/ofatumumab (N = 20) . | Group 3: ofatumumab → ibrutinib (N = 24) . | All patients (N = 71) . |
|---|---|---|---|---|
| Median number (range) of prior systemic therapies | 3 (2-10) | 3 (2-13) | 4 (2-12) | 3 (2-13) |
| Types of prior systemic therapy, n (%) | ||||
| Immunotherapy | ||||
| Antibody therapy | 27 (100) | 20 (100) | 24 (100) | 71 (100) |
| Rituximab | 26 (96) | 20 (100) | 24 (100) | 70 (99) |
| Alemtuzumab | 4 (15) | 1 (5) | 4 (17) | 9 (13) |
| Corticosteroids | 15 (56) | 10 (50) | 14 (58) | 39 (55) |
| Chemotherapy | ||||
| Purine analogs | 24 (89) | 20 (100) | 21 (88) | 65 (92) |
| Alkylating agents | 20 (74) | 9 (45) | 14 (58) | 43 (61) |
| Anthracyclines | 6 (22) | 2 (10) | 2 (8) | 10 (14) |
| Other therapy | ||||
| Small molecule | 9 (33) | 5 (25) | 6 (25) | 20 (28) |
| Immunomodulating agent | 8 (30) | 4 (20) | 5 (21) | 17 (24) |
| . | Group 1: ibrutinib → ofatumumab (N = 27) . | Group 2: ibrutinib/ofatumumab (N = 20) . | Group 3: ofatumumab → ibrutinib (N = 24) . | All patients (N = 71) . |
|---|---|---|---|---|
| Median number (range) of prior systemic therapies | 3 (2-10) | 3 (2-13) | 4 (2-12) | 3 (2-13) |
| Types of prior systemic therapy, n (%) | ||||
| Immunotherapy | ||||
| Antibody therapy | 27 (100) | 20 (100) | 24 (100) | 71 (100) |
| Rituximab | 26 (96) | 20 (100) | 24 (100) | 70 (99) |
| Alemtuzumab | 4 (15) | 1 (5) | 4 (17) | 9 (13) |
| Corticosteroids | 15 (56) | 10 (50) | 14 (58) | 39 (55) |
| Chemotherapy | ||||
| Purine analogs | 24 (89) | 20 (100) | 21 (88) | 65 (92) |
| Alkylating agents | 20 (74) | 9 (45) | 14 (58) | 43 (61) |
| Anthracyclines | 6 (22) | 2 (10) | 2 (8) | 10 (14) |
| Other therapy | ||||
| Small molecule | 9 (33) | 5 (25) | 6 (25) | 20 (28) |
| Immunomodulating agent | 8 (30) | 4 (20) | 5 (21) | 17 (24) |